Related Experiment Video
Updated: Jul 2, 2025
Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
Published on: March 3, 2023
The therapeutic effect of mesenchymal stem cells in diabetic kidney disease
Umm E Habiba1,2, Nasar Khan3,4,5, David Lawrence Greene6,7,8
1Pak-American Hospital Pvt. Ltd, Jahangir Multiplex, Peshawar Road, Sector H-13, Islamabad, 44000, Pakistan. uhabiba@r3stemcell.com.
Abstract:
Diabetes mellitus (DM) often causes chronic kidney damage despite best medical practices. Diabetic kidney disease (DKD) arises from a complex interaction of factors within the kidney and the whole body. Targeting specific disease-causing agents using drugs has not been effective in treating DKD. However, stem cell therapies offer a promising alternative by addressing multiple disease pathways and promoting kidney regeneration. Mesenchymal stem cells (MSCs) offer great promise due to their superior accessibility ratio from adult tissues and remarkable modes of action, such as the production of paracrine anti-inflammatory and cytoprotective substances. This review critically evaluates the development of MSC treatment for DKD as it moves closer to clinical application. Results from animal models suggest that systemic MSC infusion may positively impact DKD progression. However, few registered and completed clinical trials exist, and whether the treatments are effective in humans is still being determined. Significant knowledge gaps and research opportunities exist, including establishing the ideal source, dose, and timing of MSC delivery, better understanding of in vivo mechanisms, and developing quantitative indicators to obtain a more significant therapeutic response. This paper reviews recent literature on using MSCs in preclinical and clinical trials in DKD. Potent biomarkers related to DKD are also highlighted, which may help better understand MSCs' action in this disease progression. KEY MESSAGES: Mesenchymal stem cells have anti-inflammatory and paracrine effects in diabetic kidney disease. Mesenchymal stem cells alleviate in animal models having diabetic kidney disease. Mesenchymal stem cells possess promise for the treatment of diabetic kidney disease.
Insights
Mesenchymal stem cells (MSCs) show promise for treating diabetic kidney disease (DKD) by reducing inflammation and aiding regeneration. While effective in animal models, human clinical trial results are still pending, requiring further research on optimal treatment protocols.
Area of Science:
- Nephrology
- Regenerative Medicine
- Stem Cell Biology
Background:
- Diabetic kidney disease (DKD) is a major complication of diabetes mellitus, often resistant to conventional therapies.
- Current drug treatments targeting specific pathways have limited efficacy in halting DKD progression.
- Stem cell therapy presents a novel approach to address multifactorial DKD pathology and promote kidney repair.
Approach:
- This review synthesitsizes current research on mesenchymal stem cell (MSC) applications for DKD.
- It evaluates preclinical findings in animal models and ongoing human clinical trials.
- The review highlights the mechanisms of MSC action, including paracrine and anti-inflammatory effects.
Key Points:
- MSCs demonstrate significant therapeutic potential in preclinical DKD models.
- Their anti-inflammatory and cytoprotective paracrine actions are key to their efficacy.
- Few human clinical trials have been completed, necessitating further investigation.
Conclusions:
- MSC therapy holds considerable promise for treating diabetic kidney disease.
- Further research is crucial to optimize MSC delivery, dosage, and timing for clinical success.
- Identifying robust biomarkers is essential for monitoring MSC efficacy in DKD patients.
More Related Videos
08:09Isolation of Rat Adipose Tissue Mesenchymal Stem Cells for Differentiation into Insulin-producing Cells
Published on: August 29, 2022
10:37Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
